Skip to content
Screener

CG Oncology CGON Debt-to-equity

Debt-to-equity at other companies

Pfizer logo
PfizerPFE
0.7×0.0×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.6×-0.1×
Gilead Sciences logo
Gilead SciencesGILD
2.2×+1.0×
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
0.2×0.0×
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
0.9×0.0×
UroGen Pharma logo
UroGen PharmaURGN
4.8×—

Other financials

Income statement

See full
Revenue$1.2M—
Operating income-$86.4M-77.3%
Net income-$79.1M-90.8%
EPS (diluted)-$0.90-66.7%

Balance sheet

See full
Cash & equivalents$19.6M+34.3%
Total debt$8.8M+787%
Total equity$1.0B+53.5%
Total assets$1.1B+54.8%

Cash flow

See full
Operating cash flow-$46.4M-66.0%
CapEx$468.0K+3,243%
Free cash flow-$46.9M-67.6%

Valuation

See full
Market cap$6.6B+242%
Enterprise value$6.59B+244%
P/S1,060×-2,439×

Profitability

See full
Operating margin-4,056.2%-1,873pp
Net margin-3,602.7%-1,650pp
FCF margin-2,879.6%-1,307pp

Returns & leverage

See full
Return on equity-26.4%+9.3pp
Current ratio22.2×+0.1×

Where this comes from

Calculated from CG Oncology’s reported figures.

total debt/total stockholders equity=0×

Based on the most recent quarter.

The source filing: CG Oncology’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 8:45 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336918

FAQ

What is CG Oncology's debt-to-equity?
CG Oncology (CGON) reported debt-to-equity of 0× in Q2 2026.
How has CG Oncology's debt-to-equity changed year-over-year?
CG Oncology's debt-to-equity increased by 473.3% year-over-year, from 0× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about CG Oncology's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude